Home›Neratinib

Neratinib

Also known as: Nerlynx

Route: Oral

10 interactions on record

Neratinib has 10 known drug interactions based on U.S. FDA drug labeling data. Of these, 6 are contraindicated combinations that should be avoided entirely. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Lopinavir And Ritonavir, Mao Inhibitors, Ritonavir. Patients taking Neratinib should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 10
Contraindicated: 6
Major: 3
Moderate: 1

Contraindicated (6)

Neratinib + Lopinavir And Ritonavir— Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, veneto…
Neratinib + Mao Inhibitors— Concomitant use increases neratinib Cmax and AUC, increasing risk of NERLYNX toxicity. Avoid concomitant use.
Neratinib + Ritonavir— Anticancer Agents: abemaciclib, apalutamide, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, veneto…
Neratinib + Ritonavir 100 Mg— Anticancer Agents: abemaciclib, apalutamide, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, veneto…
Neratinib + Strong Cyp3a4 And P-Glycoprotein Inducers— Concomitant use may increase neratinib Cmax and AUC, increasing risk of NERLYNX toxicity. Avoid concomitant use.
Neratinib + Strong Or Moderate Cyp3a Inducers— Concomitant use reduces neratinib Cmax and AUC, reducing NERLYNX activity. Avoid concomitant use.

Major (3)

Neratinib + Anakinra— Concomitant use may decrease neratinib AUC, reducing NERLYNX activity. Separate administration by at least 2 hours befor…
Neratinib + Antacids Containing Calcium— Concomitant use may decrease neratinib AUC, reducing NERLYNX activity. Separate administration by at least 3 hours after…
Neratinib + Nirmatrelvir And Ritonavir— Anticancer drugs abemaciclib, ceritinib, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax…

Moderate (1)

Neratinib + Anti-Platelet Agents— NERLYNX increases concentrations of P-gp substrates, which may increase risk of adverse reactions. Monitor for adverse r…

Neratinib + Lopinavir And Ritonavir⛔Contraindicated

Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer agents ↓lopinavir/ritonavir # Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to KALETRA or to the class of protease inhibitors [see Contraindications ( 4 )] . Avoid use of neratinib, venetoclax or ibrutinib with KALETRA.

Neratinib + Mao Inhibitors⛔Contraindicated

Concomitant use increases neratinib Cmax and AUC, increasing risk of NERLYNX toxicity. Avoid concomitant use.

Neratinib + Ritonavir⛔Contraindicated

Anticancer Agents: abemaciclib, apalutamide, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer agents ↓ ritonavir # Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to NORVIR or to the class of protease inhibitors [see Contraindications ( 4 ) ] . Avoid use of neratinib, venetoclax or ibrutinib with NORVIR.

Neratinib + Ritonavir 100 Mg⛔Contraindicated

Anticancer Agents: abemaciclib, apalutamide, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer agents ↓ ritonavir # Apalutamide is contraindicated due to potential for loss of virologic response and possible resistance to ritonavir or to the class of protease inhibitors [see Contraindications ( 4 )]. Avoid use of neratinib, venetoclax or ibrutinib with ritonavir.

Neratinib + Strong Cyp3a4 And P-Glycoprotein Inducers⛔Contraindicated

Concomitant use may increase neratinib Cmax and AUC, increasing risk of NERLYNX toxicity. Avoid concomitant use.

Neratinib + Strong Or Moderate Cyp3a Inducers⛔Contraindicated

Concomitant use reduces neratinib Cmax and AUC, reducing NERLYNX activity. Avoid concomitant use.

Neratinib + Anakinra⚠️Major

Concomitant use may decrease neratinib AUC, reducing NERLYNX activity. Separate administration by at least 2 hours before or 10 hours after.

Neratinib + Antacids Containing Calcium⚠️Major

Concomitant use may decrease neratinib AUC, reducing NERLYNX activity. Separate administration by at least 3 hours after antacid dose.

Neratinib + Nirmatrelvir And Ritonavir⚠️Major

Anticancer drugs abemaciclib, ceritinib, dasatinib, encorafenib, ibrutinib, ivosidenib, neratinib, nilotinib, venetoclax, vinblastine, vincristine ↑ anticancer drugs Avoid co-administration of encorafenib or ivosidenib due to potential risk of serious adverse events such as QT interval prolongation. Avoid use of neratinib, venetoclax or ibrutinib.

Neratinib + Anti-Platelet Agents🟡Moderate

NERLYNX increases concentrations of P-gp substrates, which may increase risk of adverse reactions. Monitor for adverse reactions, especially those sensitive to minimal concentration changes.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.